FCM
ITRM

Flinton Capital Management’s Iterum Therapeutics ITRM Stock Holding History

Flinton Capital Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$196K Sell
2,212
-91
-4% -$8.86K 0.01% 674
2019
Q2 		$238K Sell
2,303
-430
-16% -$47.8K 0.01% 656
2019
Q1 		$329K Sell
2,733
-653
-19% -$59.9K 0.01% 565
2018
Q4 		$254K Hold
3,386
– – 0.01% 604
2018
Q3 		$340K Sell
3,386
-17
-0.5% -$2.22K 0.01% 602
2018
Q2 		$556K Buy
+3,403
New +$614K 0.02% 410

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return

Flinton Capital Management's ITRM Position: Q3 2019 in Review

Flinton Capital Management reduced its Iterum Therapeutics (ITRM) stake by 4% in Q3 2019, selling an estimated $8.86K and leaving 2,212 shares worth $196K. The position accounts for 0.01% of the portfolio, ranked #674.

Flinton Capital Management first reported a position in ITRM in Q2 2018 and has held it in 6 quarters since. The position peaked at $556K in Q2 2018. 19 funds tracked by Wall St. Rank hold ITRM as of Q3 2019.

  • Flinton Capital Management held 2,212 shares of Iterum Therapeutics worth $196K as of Q3 2019.
  • Flinton Capital Management sold 91 Iterum Therapeutics shares in Q3 2019, an estimated $8.86K.
  • Iterum Therapeutics made up 0.01% of Flinton Capital Management's portfolio in Q3 2019, its #674 holding.
  • Flinton Capital Management first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Flinton Capital Management's Iterum Therapeutics position peaked at $556K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.